ALYREF and non-small cell lung carcinoma: In conclusion, we showed for the first time, to the best of our knowledge, that a new lncRNA, LINC01259, promoted NSCLC progression by interacting with m5C modifier ALYREF to increase YAP1 m5C level and mRNA stability and expression (Fig. 7).